Analyses of objective response rate, progression‐free survival, and adverse events in hepatocellular carcinoma patients treated with lenvatinib: A multicenter retrospective study-Reference-Cited by-同舟云学术

Analyses of objective response rate, progression‐free survival, and adverse events in hepatocellular carcinoma patients treated with lenvatinib: A multicenter retrospective study

Published:2019-12-10 Issue:3 Volume:50 Page:382-395
ISSN:1386-6346
Container-title:Hepatology Research
language:en
Short-container-title:Hepatol Res

Author:

Hatanaka Takeshi¹^ORCID,Kakizaki Satoru²^ORCID,Nagashima Tamon³,Namikawa Masashi⁴,Tojima Hiroki²^ORCID,Shimada Yasushi⁵,Takizawa Daichi⁶,Naganuma Atsushi⁷^ORCID,Arai Hirotaka⁶^ORCID,Sato Ken²^ORCID,Harimoto Norifumi⁸,Shirabe Ken⁸,Uraoka Toshio²

Affiliation:

1. Department of GastroenterologyGunma Saiseikai Maebashi Hospital

2. Department of Gastroenterology and HepatologyGunma University Graduate School of Medicine

3. Department of GastroenterologyNational Hospital Organization Shibukawa Medical Center

4. Department of Internal MedicineKiryu Kosei General Hospital

5. Department of Internal MedicineIsesaki Municipal Hospital

6. Department of GastroenterologyMaebashi Red Cross Hospital

7. Department of GastroenterologyNational Hospital Organization Takasaki General Medical Center

8. Department of Hepatobiliary and Pancreatic SurgeryGunma University Graduate School of Medicine

Publisher

Wiley

Subject